Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)
Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –
Innoviva r&d expenses
Research and development expenses are spending on new products and technology.
Innoviva's R&D Expenses for the twelve months ending Sep 30, 2026 was $20.20M, down 32.0% year over year. For fiscal 2025 it was $30.60M, up 124.1% from the year before. Over ten years it grew 27.9% a year on average. The highest annual figure on record is $103.57M in fiscal 2011.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.60M | +124.1% |
| FY2024 | Dec 31, 2024 | $13.65M | -59.7% |
| FY2023 | Dec 31, 2023 | $33.92M | -18.1% |
| FY2022 | Dec 31, 2022 | $41.43M | +7093.1% |
| FY2021 | Dec 31, 2021 | $576.00K | -67.8% |
| FY2020 | Dec 31, 2020 | $1.79M | – |
| FY2019 | Dec 31, 2019 | $0 | – |
| FY2018 | Dec 31, 2018 | $0 | -100.0% |
| FY2017 | Dec 31, 2017 | $1.36M | -2.7% |
| FY2016 | Dec 31, 2016 | $1.39M | -46.8% |
| FY2015 | Dec 31, 2015 | $2.62M | -65.1% |
| FY2014 | Dec 31, 2014 | $7.50M | -17.0% |
| FY2013 | Dec 31, 2013 | $9.04M | +10.9% |
| FY2012 | Dec 31, 2012 | $8.15M | -92.1% |
| FY2011 | Dec 31, 2011 | $103.57M | +38.0% |
| FY2010 | Dec 31, 2010 | $75.07M | -3.2% |
| FY2009 | Dec 31, 2009 | $77.52M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.21M | -61.9% |
| Q2 FY2026 | Jun 30, 2026 | $5.19M | -35.0% |
| Q1 FY2026 | Mar 31, 2026 | $5.24M | +19.2% |
| Q4 FY2025 | Dec 31, 2025 | $4.56M | +24.3% |
| Q3 FY2025 | Sep 30, 2025 | $13.67M | +285.0% |
| Q2 FY2025 | Jun 30, 2025 | $7.98M | +211.8% |
| Q1 FY2025 | Mar 31, 2025 | $4.40M | +13.4% |
| Q4 FY2024 | Dec 31, 2024 | $3.67M | +55.6% |
| Q3 FY2024 | Sep 30, 2024 | $3.55M | -11.0% |
| Q2 FY2024 | Jun 30, 2024 | $2.56M | -82.9% |
| Q1 FY2024 | Mar 31, 2024 | $3.88M | -69.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.36M | -76.4% |
| Q3 FY2023 | Sep 30, 2023 | $3.99M | -66.0% |
| Q2 FY2023 | Jun 30, 2023 | $14.99M | +8.0% |
| Q1 FY2023 | Mar 31, 2023 | $12.59M | +115.6% |
| Q4 FY2022 | Dec 31, 2022 | $9.99M | +24862.5% |
| Q3 FY2022 | Sep 30, 2022 | $11.73M | +2511.4% |
| Q2 FY2022 | Jun 30, 2022 | $13.88M | +36436.8% |
| Q1 FY2022 | Mar 31, 2022 | $5.84M | +11814.3% |
| Q4 FY2021 | Dec 31, 2021 | $40.00K | -81.7% |
| Q3 FY2021 | Sep 30, 2021 | $449.00K | -55.5% |
| Q2 FY2021 | Jun 30, 2021 | $38.00K | -93.2% |
| Q1 FY2021 | Mar 31, 2021 | $49.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $219.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $1.01M | – |
| Q2 FY2020 | Jun 30, 2020 | $559.00K | – |
| Q1 FY2020 | Mar 31, 2020 | $0 | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
| Q3 FY2019 | Sep 30, 2019 | $0 | – |
| Q2 FY2019 | Jun 30, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | -100.0% |
| Q3 FY2018 | Sep 30, 2018 | $0 | -100.0% |
| Q2 FY2018 | Jun 30, 2018 | $0 | -100.0% |
| Q1 FY2018 | Mar 31, 2018 | $0 | -100.0% |
| Q4 FY2017 | Dec 31, 2017 | $342.00K | -0.9% |
| Q3 FY2017 | Sep 30, 2017 | $311.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $348.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $354.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $345.00K | – |
See a number that looks wrong?